Literature DB >> 16931768

Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5).

Thomas J Urban1, Renata C Gallagher, Chaline Brown, Richard A Castro, Leah L Lagpacan, Claire M Brett, Travis R Taylor, Elaine J Carlson, Thomas E Ferrin, Esteban G Burchard, Seymour Packman, Kathleen M Giacomini.   

Abstract

Systemic carnitine deficiency (SCD) is a rare autosomal recessive disease resulting from defects in the OCTN2 (SLC22A5) gene, which encodes the high-affinity plasma membrane carnitine transporter. Although OCTN2 is fairly well studied in its relationship with SCD, little is known about the carrier frequency of disease-causing alleles of OCTN2, or of more common functional polymorphisms in this gene. To address these issues, we screened for genetic variants in the OCTN2 coding region by direct sequencing of the exons and flanking intronic region of OCTN2 in a large sample (n = 276) of ethnically diverse subjects. In addition, we established lymphoblastoid cell lines from subjects homozygous for either allele of the previously identified promoter region variant, -207G>C. We found eight amino acid sequence variants of OCTN2, of which three (Phe17Leu, Leu144Phe, and Pro549Ser) were polymorphic in at least one ethnic group. When assayed for functional activity by expression in human embryonic kidney 293 cells, using as probes both the endogenous substrate (l-carnitine) and the organic cation tetraethylammonium, three variants showed functional differences from the reference OCTN2 (Phe17Leu, Tyr449Asp, Val481Phe; p < 0.05). Further studies of the Phe17Leu polymorphism showed a reduced V(max) for l-carnitine transport to approximately 50% of the reference OCTN2. Confocal microscopy studies using an OCTN2-GFP fusion protein showed that Phe17Leu had distinct subcellular localization from the reference OCTN2, with diffuse cytoplasmic retention of Phe17Leu, in contrast to reference OCTN2, which localized specifically to the plasma membrane. Lymphoblasts from subjects homozygous for the -207G allele showed increased l-carnitine transport compared with the -207C/C homozygotes (p < 0.05). This study suggests that although loss-of-function mutations in OCTN2 are likely to be rare, common variants of OCTN2 found in healthy populations may contribute to variation in the disposition of carnitine and some clinically used drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931768     DOI: 10.1124/mol.106.028126

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.

Authors:  Ningwu Huang; Vishal Agrawal; Kathleen M Giacomini; Walter L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

Review 2.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

3.  Functional and molecular studies in primary carnitine deficiency.

Authors:  Marta Frigeni; Bijina Balakrishnan; Xue Yin; Fernanda R O Calderon; Rong Mao; Marzia Pasquali; Nicola Longo
Journal:  Hum Mutat       Date:  2017-09-14       Impact factor: 4.878

4.  Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Authors:  Harunobu Tahara; Sook Wah Yee; Thomas J Urban; Stephanie Hesselson; Richard A Castro; Michiko Kawamoto; Doug Stryke; Susan J Johns; Thomas E Ferrin; Pui-Yan Kwok; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

Review 5.  The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.

Authors:  D L Kroetz; S W Yee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2009-11-25       Impact factor: 6.875

6.  Population pharmacokinetic study of memantine: effects of clinical and genetic factors.

Authors:  Muriel Noetzli; Monia Guidi; Karsten Ebbing; Stephan Eyer; Laurence Wilhelm; Agnès Michon; Valérie Thomazic; Abdel-Messieh Alnawaqil; Sophie Maurer; Serge Zumbach; Panteleimon Giannakopoulos; Armin von Gunten; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

7.  Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP.

Authors:  Cheryl D Cropp; Takafumi Komori; James E Shima; Thomas J Urban; Sook Wah Yee; Swati S More; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2008-01-23       Impact factor: 4.436

8.  The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.

Authors:  Nada Abla; Leslie W Chinn; Tsutomu Nakamura; Li Liu; Conrad C Huang; Susan J Johns; Michiko Kawamoto; Doug Stryke; Travis R Taylor; Thomas E Ferrin; Kathleen M Giacomini; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-03-25       Impact factor: 4.030

9.  Cardiomyopathy and carnitine deficiency.

Authors:  Cristina Amat di San Filippo; Matthew R G Taylor; Luisa Mestroni; Lorenzo D Botto; Nicola Longo
Journal:  Mol Genet Metab       Date:  2008-03-11       Impact factor: 4.797

Review 10.  Carnitine transport and fatty acid oxidation.

Authors:  Nicola Longo; Marta Frigeni; Marzia Pasquali
Journal:  Biochim Biophys Acta       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.